Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$18.9 million.

  • Foghorn Therapeutics' Free Cash Flow rose 1151.36% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.9 million, marking a year-over-year increase of 1445.35%. This contributed to the annual value of -$101.3 million for FY2024, which is 1509.93% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Free Cash Flow stood at -$18.9 million for Q3 2025, which was up 1151.36% from -$21.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Free Cash Flow high stood at $271.3 million for Q1 2022, and its period low was -$32.6 million during Q2 2023.
  • Over the past 5 years, Foghorn Therapeutics' median Free Cash Flow value was -$24.9 million (recorded in 2021), while the average stood at -$7.7 million.
  • In the last 5 years, Foghorn Therapeutics' Free Cash Flow tumbled by 66813.63% in 2021 and then soared by 118771.5% in 2022.
  • Over the past 5 years, Foghorn Therapeutics' Free Cash Flow (Quarter) stood at $11.8 million in 2021, then tumbled by 347.36% to -$29.2 million in 2022, then rose by 5.53% to -$27.6 million in 2023, then rose by 9.36% to -$25.0 million in 2024, then rose by 24.55% to -$18.9 million in 2025.
  • Its Free Cash Flow was -$18.9 million in Q3 2025, compared to -$21.0 million in Q2 2025 and -$24.0 million in Q1 2025.